Company Encyclopedia
View More
name
HENGRUI PHARMA
01276.HK
Jiangsu Hengrui Pharmaceuticals Co.,Ltd, a pharmaceutical company, researches, develops, manufactures, and commercializes medicines to address unmet clinical needs in China and internationally. It develops medicines in the areas of oncology, metabolic and cardiovascular, immunological and respiratory, neuroscience, pain management, infectious, respiratory system, hematological, ophthalmology, and autoimmune and other diseases. The company was founded in 1970 and is headquartered in Lianyungang, China.
1.419 T
01276.HKMarket value -Rank by Market Cap -/-

Financial Score

21/12/2025 Update
B
PharmaceuticalsIndustry
Industry Ranking1/48
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreA
    • ROE14.46%A
    • Profit Margin24.10%A
    • Gross Margin85.58%A
  • Growth ScoreB
    • Revenue YoY17.97%B
    • Net Profit YoY35.67%B
    • Total Assets YoY39.40%A
    • Net Assets YoY33.55%A
  • Cash ScoreB
    • Cash Flow Margin414.88%C
    • OCF YoY17.97%B
  • Operating ScoreC
    • Turnover0.53C
  • Debt ScoreA
    • Gearing Ratio12.14%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Hengrui Pharma's five subsidiaries have been approved to conduct clinical trials for drugs

    Five subsidiaries of Hengrui Pharma have been approved by the National Medical Products Administration to conduct multiple clinical trials for drugs, including treatments for prostate cancer, overweight, or obesity

    AASTOCKS·
    SH
    600276
    +1.42%
    HK
    01276
    +0.07%
    AASTOCKS·
    SH
    600276
    +1.42%
    HK
    01276
    +0.07%

    Hengrui Pharma's four subsidiaries have been approved to conduct clinical trials for drugs

    Four subsidiaries of Hengrui Pharma have been approved by the National Medical Products Administration to conduct multiple clinical trials for drugs, including those for the treatment of heart failure, metabolic-associated fatty liver disease, chronic sinusitis, chronic obstructive pulmonary disease, and advanced solid tumors

    AASTOCKS·
    SH
    600276
    +1.42%
    HK
    01276
    +0.07%
    AASTOCKS·
    SH
    600276
    +1.42%
    HK
    01276
    +0.07%

    Top 5 HK Stock Gainers/Losers (>100B) (12.12)

    CGS(06881) rose 6.97%, with a trading turnover 575.7 Million HKD, and a year-to-date rose 59.5%. AKESO(09926) rose 6.05%, with a trading turnover 1.2 Billion HKD, and a year-to-date rose 105.1%. HENGRUI PHARMA(01276) fell 3.01%, with a trading turnover 410.5 Million HKD, and a year-to-date rose 64.5%. ABC(01288) fell 2.97%, with a trading turnover 1.2 Billion HKD, and a year-to-date rose 37.5%.

    Top Gainers & Losers·
    HK
    06881
    +0.58%
    HK
    09926
    +1.12%
    HK
    02601
    -0.95%
    Top Gainers & Losers·
    HK
    06881
    +0.58%
    HK
    09926
    +1.12%
    HK
    02601
    -0.95%

    Top 5 HK Stock Gainers/Losers (>100B) (12.9)

    HENGRUI PHARMA(01276) rose 2.41%, with a trading turnover 272.6 Million HKD, and a year-to-date rose 68.7%. HORIZONROBOT-W(09660) rose 2.35%, with a trading turnover 1.3 Billion HKD, and a year-to-date rose 141.7%. JIANGXI COPPER(00358) fell 6.51%, with a trading turnover 1.0 Billion HKD, and a year-to-date rose 198.3%. CMOC(03993) fell 6.42%, with a trading turnover 1.5 Billion HKD, and a year-to-date rose 260.4%.

    Top Gainers & Losers·
    HK
    01276
    +0.07%
    HK
    09660
    +7.04%
    HK
    02269
    +4.40%
    Top Gainers & Losers·
    HK
    01276
    +0.07%
    HK
    09660
    +7.04%
    HK
    02269
    +4.40%

    The Hang Seng Index closed up 0.13%, and the Hang Seng Tech Index rose 0.11%. Meituan increased by nearly 6%, Hengrui Pharma rose by nearly 5%, GDS surged over 3%, and JD.com rose over 2%

    Wallstreetcn·
    US
    MPNGY
    -0.84%
    HK
    03690
    +1.28%
    US
    JD
    +0.07%
    Wallstreetcn·
    US
    MPNGY
    -0.84%
    HK
    03690
    +1.28%
    US
    JD
    +0.07%
    Posts
    View More
    © 2025 Longbridge｜Disclaimer